Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c, offers guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.70, $0.10 better than the analyst estimate of $1.60. Revenue for the quarter came in at $11.48 billion versus the consensus estimate of $11.22 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2024 EPS of $7.10-$7.40, versus the consensus of $7.39.
Revenues Increasing by Low Single-Digits.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Keurig Dr Pepper coffee chief to depart ahead of planned split
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates